| 國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
CHIH-HSIN YANG; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; CHIH-HSIN YANG; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-06-27T07:07:55Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU; Chang W.-C.; Kuo H.-P.; Yu C.-T.; Lin Z.-Z.; Kao W.-Y. |
| 臺大學術典藏 |
2022-06-27T07:07:39Z |
Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study
|
Fan W.-C.; CHONG-JEN YU; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T07:06:32Z |
Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan
|
Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; Yang C.-H.; Chen Y.-M.; CHONG-JEN YU; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. |
| 臺大學術典藏 |
2022-06-27T07:01:39Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:29Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:17Z |
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
|
Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; Yu S.-L.; Su K.-Y.; CHONG-JEN YU; Ho C.C.; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Yang P.-C.; Chen J.J.W.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:12Z |
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study
|
Chang G.-C.; Tseng C.-H.; Hsu K.-H.; CHONG-JEN YU; Yang C.-T.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Liu C.-Y.; Liao W.-Y.; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; Tsai Y.-H.; Hsieh M.-J.; Wu W.-S.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2022-06-27T02:49:09Z |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su P.-L.; Chang G.-C.; Hsiao S.-H.; Hsia T.-C.; Lin M.-C.; Lin M.-H.; JIN-YUAN SHIH; Yang C.-T.; Yang S.-H.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T02:49:08Z |
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
|
Popat S.; Hsia T.-C.; Hung J.-Y.; Jung H.A.; JIN-YUAN SHIH; Park C.K.; Lee S.H.; Okamoto T.; Ahn H.K.; Lee Y.C.; Sato Y.; Lee S.S.; Mascaux C.; Daoud H.; M?rten A.; Miura S. |
| 臺大學術典藏 |
2022-06-10T06:11:15Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 國立成功大學 |
2022 |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su, P.-L.;Chang, G.-C.;Hsiao, S.-H.;Hsia, T.-C.;Lin, M.-C.;Lin, M.-H.;Shih, J.-Y.;Yang, C.-T.;Yang, S.-H.;Chen, Y.-M. |
| 國立成功大學 |
2022 |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu, S.;Wang, Q.;Zhang, G.;Dong, X.;Yang, C.-T.;Song, Y.;Chang, G.-C.;Lu, Y.;Pan, H.;Chiu, Chiu C.-H.;Wang, Z.;Feng, J.;Zhou, J.;Xu, Xu X.;Guo, R.;Chen, J.;Yang, H.;Chen, Y.;Yu, Z.;Shiah, H.-S.;Wang, C.-C.;Yang, N.;Fang, J.;Wang, P.;Wang, K.;Hu, Y.;He, J.;Wang, Z.;Shi, J.;Chen, S.;Wu, Q.;Sun, C.;Li, C.;Wei, H.;Cheng, Y.;Su, W.-C.;Hsia, T.-C.;Cui, J.;Sun, Y.;Ou, S.-H.I.;Zhu, V.W.;Chih-Hsin, Yang J. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2021-10-04T07:15:40Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 臺大學術典藏 |
2021-08-20T08:00:37Z |
Lung Cancer in Republic of China
|
Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; Yang J.C.-H.; BIN-CHI LIAO; Hsia T.-C.; Chen Y.-M. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 臺大學術典藏 |
2021-05-02T03:49:14Z |
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
|
Wu S.-G.;Chiang C.-L.;Liu C.-Y.;Wang C.-C.;Su P.-L.;Hsia T.-C.;Jin-Yuan Shih;Chang G.-C.; Wu S.-G.; Chiang C.-L.; Liu C.-Y.; Wang C.-C.; Su P.-L.; Hsia T.-C.; JIN-YUAN SHIH; Chang G.-C. |
